Pushkal Garg Sells 1,510 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Pushkal Garg sold 1,510 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $547,933.70. Following the sale, the executive vice president owned 22,511 shares in the company, valued at approximately $8,168,566.57. This trade represents a 6.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Alnylam Pharmaceuticals Trading Down 0.8%

Shares of ALNY traded down $3.10 during mid-day trading on Wednesday, reaching $366.86. 1,250,033 shares of the company were exchanged, compared to its average volume of 1,593,122. The company has a debt-to-equity ratio of 4.45, a quick ratio of 2.49 and a current ratio of 2.54. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The business has a 50 day simple moving average of $423.39 and a two-hundred day simple moving average of $421.94. The stock has a market capitalization of $48.47 billion, a PE ratio of 1,528.58 and a beta of 0.32.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Needham & Company reiterated a bullish outlook and forecasted strong price appreciation for ALNY, giving investors a counterpoint to bearish views and providing potential support for the stock. Needham Bullish Forecast
• Positive Sentiment: Alnylam presented at the J.P. Morgan Healthcare Conference (transcript available) — management used the forum to outline development priorities and the Alnylam 2030 growth plan, keeping the company in front of institutional investors. JPM Presentation Transcript
• Neutral Sentiment: Analysis pieces are digesting the Alnylam 2030 plan and new 2026 guidance; valuation write-ups provide scenarios but do not change fundamentals immediately. These pieces are useful for longer-term investors assessing the plan vs. current multiples. Valuation After 2030 Plan
• Neutral Sentiment: CEO interviews and conference coverage (video/interview links) elaborate on development goals and timelines; useful for due diligence but contain no immediate new financials. CEO Interview
• Neutral Sentiment: Industry roundups from JPM/BioWorld reference Alnylam within broader biopharma Q4 revenue and guidance commentary — helpful context but not company-specific catalysts. Bioworld JPM Coverage
• Neutral Sentiment: Reported short-interest data appears anomalous (shows zero shares and NaN changes), so it should not be treated as signal until corrected by exchanges. No link (data issue)
• Negative Sentiment: Insider selling: CEO Yvonne Greenstreet and multiple EVPs sold shares on Jan 12–13 (CEO sale ~9,577 shares; several EVPs sold 1,510–2,780 shares each). Collectively these disclosed sales totaled roughly $7M, which markets often view as a near-term negative signal even if sales are for personal/diversification reasons. CEO SEC Filing
• Negative Sentiment: Bank of America published a pessimistic price forecast for ALNY, which can weigh on sentiment among institutional and retail investors. BofA Pessimistic Forecast
• Negative Sentiment: News coverage highlighted a sharp intraday sell-off (article noting ~9% drop) after the company unveiled ambitious 2026 guidance and its Alnylam 2030 plan — the market appears to be re-pricing risk around execution and near-term guidance. Coverage of the Sell-off

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ALNY. Northwest Wealth Management LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth $225,000. Eastern Bank purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $42,000. USA Financial Formulas bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $169,000. Kaufman Rossin Wealth LLC increased its holdings in Alnylam Pharmaceuticals by 55.1% in the 4th quarter. Kaufman Rossin Wealth LLC now owns 749 shares of the biopharmaceutical company’s stock worth $298,000 after buying an additional 266 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in Alnylam Pharmaceuticals by 13.9% in the fourth quarter. Exchange Traded Concepts LLC now owns 2,361 shares of the biopharmaceutical company’s stock worth $939,000 after purchasing an additional 288 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on ALNY. Piper Sandler restated an “overweight” rating and issued a $489.00 target price (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Leerink Partners decreased their price target on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research note on Monday, December 15th. HC Wainwright set a $570.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Oppenheimer began coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price target for the company. Twenty-two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $490.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.